Shareholders are an essential asset to any business. Through their financial investment into the future of the company, MVP can invest in developing new products, exploring opportunities in international markets and building a business which will reward them with significant returns.
As a company listed on the ASX, MVP has the responsibility to report to their shareholders through annual reports and ASX announcements. All shareholder information is now available here with links and downloadable reports.
If you would like to invest in MDI shares, the ASX code is MVP, so contact your broker for more details.
2022 $30M Capital Raise
MVP today announces a fully underwritten capital raising of $30m, comprising a $15m placement and a $15m pro rata accelerated non renounceable entitlement offer.
MVP – ASX Announcement – Launch of capital raising
For Capital Raising Presentation – August 22
MVP Prospectus – Entitlement Offer and Options
For Target Market Determination
US FDA Investor Presentation
View the Investor presentation (3rd March 2022).
FY22 Half Year Results
MVP’s Half Year Results were released on Thursday, 24 February 2022.
A recording of the CEO Investor Presentation held on Friday, 25 February 2022 is provided below.
ASX Announcements
The following are downloads of MVP’s announcements to the ASX (please note that purely technical/compliance related notices are not posted here, but can be obtained from the ASX at www.asx.com.au if required).
For 2022 announcements please click here
CEO Investor Presentation
For the latest MVP CEO Investor Presentation slides, please click on the following – MVP FY22 HY Investor Presentation
A recording of the presentation can also be viewed below
ASX Share Information
Loading 
Please Note: Price data in the above table is delayed by at least 20 minutes as required by the ASX. View MVP on ASX website.